The week in pharma: action, reaction and insight – week to February 11, 2022
By Barbara Obstoj-Cardwell. Editor
Research news last week saw US cancer focussed firm Karyopharm Therapeutics release a bullish review of new Phase III data on its endometrial cancer candidate selinexor. Financial results were also in focus. Pfizer, the world’s largest prescription medicines maker last Tuesday reported record fourth quarter 2021 figures, boosted by its hugely successful covid vaccine Comirnaty but issued conservative longer-term guidance. UK-based AstraZeneca also announced financials which pleased markets but also raised some questions regarding its vaccine rollout. On the regulatory front, a US Food and Drug Administration advisory committee voted against approval of Eli Lilly and Innovent’s lung cancer candidate sintilimab, citing the grounds of a China-based clinical trial backing the application as not appropriate.
Karyopharm fishes for a win as its solid tumor bid flounders
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze